Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

First Patient Dosed in Phase 2a Sibofimloc Trial for Crohn's disease

americanpharmaceuticalreviewSeptember 30, 2020

Tag: Enterome , sibofimloc , Crohn's disease , FimH

PharmaSources Customer Service